The FDA has expanded the frontline melanoma indications for nivolumab (Opdivo) as a single agent and in combination with ipilimumab (Yervoy) to include patients with BRAF V600 mutations, based on data from the phase III CheckMate-067 trial.
Publications
Cleveland clinic finds pregnancy-associated melanoma is associated with higher death rates
Wednesday, Jan. 20, 2016, CLEVELAND: Melanoma, the deadliest form of skin cancer, is on the rise in women of child-bearing age. Those at the greatest risk, according to new Cleveland Clinic research, are women younger than 50 who are pregnant or have recently been pregnant.
Nivolumab, Contact Immunotx Treats In-Transit Melanoma
Nivolumab in combination with contact immunotherapy can successfully treat in-transit melanoma, according to two case reports published online Dec. 12 in the Journal of Dermatology
Physicians may soon have new tool to closely track severity, potential spread of metastatic melanoma
Physicians treating patients with metastatic melanoma — one of the most aggressive forms of skin cancer — may soon have a superior tool in their efforts to closely track the disease.